LAG 3 Next Generation Immunotherapy Market to Progress Upto A Whopping 6 Billion USD with a CAGR of 26.3% in the 7MM for the Forecast Period of 2025-2035, Estimates DelveInsight

The increase in the LAG 3 Next Generation Immunotherapy market size is a direct consequence of the expected entry of premium LAG-3 drugs and their readily uptake, increase in cancer incident cases, along with PD-1/PD-L1 relapsed/refractory pool, and label-expansion in multiple cancer types. In addition to this, a robust and unique pipeline (anti-LAG-3 monoclonal and bispecific antibodies along with soluble LAG-3 molecule), and improvement in the outcome of patients will also put a significant impact on the LAG 3 Next Generation Immunotherapy market size.

LAS VEGAS, May 30, 2022 /PRNewswire/ -- DelveInsight's LAG 3 Next Generation Immunotherapy Market Insights report proffers a detailed comprehension of LAG 3 Next Generation Immunotherapy market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted LAG 3 Next Generation Immunotherapy market size from 2022 to 2035 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Some of the salient features from the LAG 3 Next Generation Immunotherapy Market Report: 

• As per an analysis by DelveInsight, the LAG 3 Next Generation Immunotherapy market size in the 7MM is anticipated to grow at a CAGR of 26.3% for the period of 2025 to 2035 and reach upto USD 6 Billion in the year 2035.
• Key oncology players, such as Bristol-Myers Squibb, Merck Sharp & Dohme, Immutep, Incyte Corporation, F-star Therapeutics, EpimAb Biotherapeutics, Roche, Xencor, AnaptysBio/GlaxoSmithKline, Macrogenics, Regeneron Pharmaceuticals/Sanofi, Symphogen, etc. are involved in developing novel target LAG 3 Immunotherapy in treatment of various oncological indications.
• The LAG 3 Next Generation Immunotherapy emerging therapies that are expected to launch in the forecast period include Eftilagimod alpha, Relatlimab, Favezelimab, FS-118, Fianlimab, RG6139, and other treatments, which would lead to a significant increase in the LAG 3 Immunotherapy market size in the coming years.
• As per DelveInsight, the emerging trends in LAG 3 Next Generation Immunotherapies with continuous headway movement along with new emerging technologies for the development of targeted therapies augurs the hopes for better therapeutic alternatives leading to a surge in  the LAG 3 Next Generation Immunotherapy market.
• According to Delveinsight's analysis, the LAG 3 Next Generation Immunotherapies market is expected to show positive growth due to the launch of potential upcoming therapies in the LAG-3 target during the forecast period (2022–2035). 
• As per DelveInsight's research, the United States is going to capture the highest LAG 3 Next Generation Immunotherapy market share across the 7MM. On the other hand, Spain is likely to capture the least by 2035. 

For further information on market impact by therapies, download the LAG 3 Next Generation Immunotherapy market sample @ LAG 3 Next Generation Immunotherapy Therapeutic Scenario

LAG 3 Next Generation Immunotherapy Overview

Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function. Immunotherapy may work by stopping or slowing the growth of cancer cells, stopping cancer from spreading to other parts of the body, and helping the immune system work better at destroying cancer cells.

LAG 3 gene belongs to the immunoglobulin superfamily (IgSF) and associates with the CD3/T-cell receptor (TCR) complex. LAG 3 interacts with MHC-II to prohibit the binding of the same MHC molecule to TCR and CD4, thus directly hindering TCR signaling in the immune response. Lymphocyte-activation gene 3 (LAG 3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation, and growth. T cells are a type of white blood cell that is part of the immune system. Activation of cytotoxic T cells by antigens enables them to kill unhealthy or foreign cells. It binds MHCII molecules and modulates T-cell function than either CTLA-4 or PD-1. It acts by regulating CD8+ T Cell expansion in immune reactions that have already been initiated (inhibitory signal) and also, by increasing the Treg cell activity.

LAG 3 Next Generation Immunotherapy Market Outlook

Cancer immunotherapy and tumor microenvironment have been at the forefront of research over the past decades. Targeting immune checkpoints, especially programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) has made a breakthrough in treating advanced malignancies. However, the low response rate brings a daunting challenge, changing the focus to dig deeply into the tumor microenvironment for alternative therapeutic targets. Strikingly, the inhibitory immune checkpoint Lymphocyte Activation Gene-3 (LAG-3) holds considerable potential. LAG-3 suppresses T-cells activation and cytokine secretion, thereby ensuring immune homeostasis. It exerts differential inhibitory impacts on various types of lymphocytes and shows a remarkable synergy with PD-1 to inhibit immune responses.

LAG 3 Next Generation Immunotherapy market is anticipated to show positive growth in the coming years due to the launch of potential upcoming therapies. At present, only one LAG 3 immunotherapy treatment has been approved by the United States Food and Drug Administration (FDA). Opdualag, a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, was FDA approved for unresectable or metastatic melanoma treatment of adult and pediatric patients 12 years of age or older. The approval is based on Phase II/III RELATIVITY-047 trial.  Currently, the company is conducting multiple trials for this drug in liver cancer, NSCLC, Head and Neck Cancer, colorectal, gastric, renal, Soft Tissue Sarcoma, Chordoma, Basal Cell Carcinoma, and many others — demonstrating the asset's wide potential. 

Favezelimab (MK-4280) by Merck is a humanized, IgG4, anti-LAG-3 monoclonal antibody that prevents LAG-3 from binding to its major ligand, MHC Class II. In November 2021, the company initiated a Phase III study co-formulated favezelimab/pembrolizumab (MK-4280A) versus standard of care in subjects with previously treated metastatic PD-L1 positive colorectal cancer (MK-4280A-007).

Eftilagimod alpha (Immutep) is being investigated as a treatment option for Head and Neck Cancer, NSCLC, Breast Cancer, and other solid tumors. Apart from Eftilagimod alpha, no other LAG-3 is currently being investigated for the treatment of metastatic breast cancer. This provides an opportunity for Immutep to carve its way into the breast cancer treatment landscape.  This drug also showed promising results in the TACTI-002 (Two ACTive Immunotherapeutics) Phase II study in Head and Neck Cancer patients. Eftilagimod has been designated Fast Track status by the US FDA for use in the frontline treatment of patients with recurrent or metastatic Head and Neck Cancer.

Currently, numerous trials are undergoing in different indications for the LAG-3 target. The major indications that are anticipated to show a better outcome by the launch of novel drugs include Breast Cancer, NSCLC, Melanoma, Colorectal Cancer, Head and Neck Cancer, and others.

Discover more about therapy set to grab substantial LAG 3 Next Generation Immunotherapy market share @ LAG 3 Next Generation Immunotherapy Market Landscape

LAG 3 Next Generation Immunotherapy Pipeline Therapies and Key Companies

• Bristol-Myers Squibb: Relatlimab [BMS-986016]
• Merck Sharp & Dohme Corp: Favezelimab [MK-4280]
• Novartis: Leramilimab (LAG525)
• Immutep: Eftilagimod alpha [IMP321]
• Agenus/Incyte Corporation: INCAGN02385
• F-star Therapeutics: FS118
• EpimAb Biotherapeutics: EMB-02 
• Roche: RG6139 [RO7247669]
• Xencor: XmAb22841 [XmAb841]
• AnaptysBio/GlaxoSmithKline: Encelimab [TSR-033]
• Macrogenics: Tebotelimab [MGD013]

To know about more pipeline therapies covered in the report, visit @ LAG 3 Next Generation Immunotherapy Pipeline Analysis, Clinical Trials, and Emerging Therapies 

LAG 3 Next Generation Immunotherapy Market Dynamics

There are several factors responsible for potential growth of the LAG 3 Next Generation Immunotherapy market including upcoming launch of therapies and a robust pipeline. Also, an increase in incident cases of various solid tumors, an increase in PD-1/PD-L1 relapsed/refractory cases in various cancers, the co-expression characteristics of LAG 3 and PD-1/PDL-1 on the T cells, and market exclusivity are aspects affecting the LAG 3 Next Generation Immunotherapy market growth positively in the coming years.

On the other hand, factors such as LAG 3 clinical trial and investigational therapy failures, and lack of sufficient knowledge about LAG 3 signaling activity that has not yet been elucidated might act as certain barriers in the LAG 3 Next Generation Immunotherapy Market. In addition to that high cost of treatment, and competition from new technologies in the same space also serve as potential barriers to the LAG 3 Next Generation Immunotherapy market growth.

Despite recent advances in cancer treatment, there is still a high unmet need for new therapeutic options. Many issues remain to be addressed, and further studies in the LAG-3 field may help uncover new therapeutic targets and regimens for the treatment of patients with cancer.

Know which therapy is expected to score the touchdown first @ LAG 3 Next Generation Immunotherapy Market Landscape and Forecast

Scope of the LAG 3 Next Generation Immunotherapy Market Report

• Forecast Period: 2022-35
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key LAG 3 Next Generation Immunotherapy Companies: Bristol-Myers Squibb, Merck Sharp & Dohme, Immutep, Incyte Corporation/Agenus, F-star Therapeutics, EpimAb Biotherapeutics, Roche, Xencor, AnaptysBio/GlaxoSmithKline, Macrogenics, Regeneron Pharmaceuticals/Sanofi, Symphogen, Novartis, Crescendo Biologics, Microbio Group, Avacta, Innovent Biologics, Leads Biolabs/BeiGene, Henlius, Protheragen, and others
• Key LAG 3 Next Generation Immunotherapy Pipeline Therapies: Relatlimab, Favezelimab, Eftilagimod alpha, INCAGN02385, FS118, EMB-02, RG6139, XmAb22841, Encelimab, Tebotelimab, Fianlimab, Sym022, LAG525, and others
• LAG 3 Next Generation Immunotherapy Therapeutic Assessment: LAG 3 Next Generation Immunotherapy current marketed and emerging therapies
• LAG 3 Next Generation Immunotherapy Market Dynamics:  LAG 3 Next Generation Immunotherapy market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs
• KOL's views
• Analyst's views
• LAG 3 Next Generation Immunotherapy Market Access and Reimbursement

Request for a Webex demo of the report @ LAG 3 Next Generation Immunotherapy Therapeutics Market

Table of Contents 

Get in touch with our Business executive @ LAG 3 Next Generation Immunotherapy Regulatory and Patent Analysis 

Related Reports

Intratumoral Cancer Therapies Market

DelveInsight's 'Intratumoral Cancer Therapies Market Insights, Epidemiology and Market Forecast—2030' report delivers an in-depth understanding of the Intratumoral Cancer Therapies, market drivers, market barriers, unmet medical needs, and key companies involved like Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Takara Bio, NanOlogy,  Istari Oncology, Moderna Therapeutics, Intensity Therapeutics, and several others.

Prostate Cancer Market 

DelveInsight's "Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Prostate cancer, emerging drugs, and key companies involved like Bayer Health Care, Amgen, Janssen Pharmaceutical, Sanofi, AstraZeneca/ Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Hoffmann-La Roche, Pfizer, Clovis Oncology, Regeneron Pharmaceuticals, Suzhou Kintor Pharmaceutical, Eli Lilly and Company, and others.

CAR-T Pipeline Insights

DelveInsight's, "CAR-T Pipeline Insights, 2022," report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including, AbbVie Inc, Adaptimmune Therapeutics PLC, Amgen, Inc, Celgene, DiaCarta, Inc, Endocyte, Inc, F1 Oncology, Inc, Fate Therapeutics Inc, Gilead, Humanigen, Inc, Immune Therapeutics, Inc, Intrexon, Corp, Juno Therapeutics, Inc, Kite Pharma, Inc, Lion TCR Pte Ltd, MaxCyte, Inc, Mesoblast, Ltd. and others.

Cervical Cancer Pipeline 

DelveInsight's 'Cervical Cancer Pipeline Insight, 2022,' report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in the Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including Genentech/Roche, Iovance Biotherapeutics, Advaxis, Agenus, Akeso Biopharma, Altor BioScience, Amgen/Allergan, AstraZeneca, Avastin Biosimilars, and others

ER+/ HER2-VE Breast Cancer Pipeline

DelveInsight's, "ER+/ HER2-VE Breast Cancer - Pipeline Insight, 2022," report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in ER+/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, and key companies involved like  BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and several others.

Immune Checkpoints Activators Market

"Immune Checkpoints Activators Competitive Landscape, Technology and Pipeline Analysis, 2020" report provides comprehensive insights on the therapeutic development for this mechanism of action. The objective of the report is to establish an understanding of the therapeutic competitive landscape for Immune Checkpoints Activators, including the pipeline products in this space, and key companies involved such as Nektar Therapeutics, Abbvie, Roche, and many others.

Hereditary Transthyretin Amyloidosis (hATTR) Market 

DelveInsight's 'Hereditary Transthyretin Amyloidosis (hATTR)- Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2032' report delivers an in-depth understanding of the Hereditary Transthyretin Amyloidosis (hATTR), historical and forecasted epidemiology, current treatment practices, emerging drugs and key companies involved such as Takeda, CSL Behring, Pharming Group, BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, and others.

 Prostate Cancer Market 

DelveInsight's "Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Prostate cancer, historical and forecasted epidemiology, current treatment practices, and key companies involved like Bayer Health Care, Astellas Pharma, Amgen, Janssen Pharmaceutical, Sanofi, Orion Corporation, AstraZeneca, Janssen Research & Development, Eli Lilly and Company, eFFECTOR Therapeutics, and several others.

 Non-Small Cell Lung Cancer (NSCLC) Market

DelveInsight's 'Non-Small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology current treatment practices, emerging drugs, and key companies involved like Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company, Sanofi, Pfizer, and others.

Browse Through Our Blog Posts

• LAG 3: A Promising Next Generation Cancer Immunotherapy
• PD-1 and PDL-1 Immune Check Point Inhibitors: A Prodigious Revolution in Cancer Treatment
• Most Promising Oncological Drugs Expected to Launch in 2022

Other Trending Healthcare Reports

Mismatch Repair Deficiency Market  | Transdermal Drug Delivery Devices Market | Encephalomyelitis Market | Erectile Dysfunction Devices Market | Nosocomial Pneumonia Market | Primary Gastric Lymphoma Market | Postoperative Gastrointestinal Dysfunction Market | Keloid Market | Laryngeal Cancer Market | Pneumothorax Treatment Devices Market  | Complicated skin and soft tissue infections (cSSTI) Market  | Gallbladder Cancer Market 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg